Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
29131 | 157 | 39.7 | 57% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | AVITRIPTAN | Author keyword | 1 | 33% | 1% | 2 |
2 | ENVIRONM INJURY EPIDEMIOL TOXICOL UNIT | Address | 1 | 50% | 1% | 1 |
3 | HOMICIDE PREVENTION | Author keyword | 1 | 50% | 1% | 1 |
4 | MICROPHYSIOLOGICAL MODELING | Author keyword | 1 | 50% | 1% | 1 |
5 | NS2330 | Author keyword | 1 | 50% | 1% | 1 |
6 | ONCOL PHYSIOL | Address | 1 | 50% | 1% | 1 |
7 | PHARM INFECT DIS | Address | 1 | 50% | 1% | 1 |
8 | SUBDIRECC GEN MED USO HUMANO | Address | 1 | 50% | 1% | 1 |
9 | UNIDAD FARMACOL CLIN EXPT | Address | 1 | 50% | 1% | 1 |
10 | AUTOMATED DISPENSING SYSTEM | Author keyword | 0 | 33% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BMS 180048 | 3 | 50% | 3% | 4 |
2 | ORAL CONTRACEPTIVE STEROIDS | 1 | 11% | 8% | 12 |
3 | OXAZEPAM KINETICS | 1 | 40% | 1% | 2 |
4 | ANTIMIGRAINE AGENT | 1 | 19% | 3% | 4 |
5 | THEOPHYLLINE PHARMACOKINETICS | 1 | 14% | 3% | 5 |
6 | ANTIPYRINE PHARMACOKINETICS | 1 | 50% | 1% | 1 |
7 | CATION RANITIDINE | 1 | 50% | 1% | 1 |
8 | MIDAZOLAM PHARMACOKINETICS | 1 | 50% | 1% | 1 |
9 | RECEIVING CONJUGATED ESTROGEN | 1 | 50% | 1% | 1 |
10 | TIRILAZAD CLEARANCE | 1 | 50% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Gender Differences in Drug Bioequivalence: Time to Rethink Practices | 2013 | 4 | 5 | 80% |
Sex Differences in Drug Disposition | 2011 | 23 | 89 | 16% |
Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs | 1998 | 73 | 96 | 19% |
Hormonal Regulation of Hepatic Drug-Metabolizing Enzyme Activity During Adolescence | 2008 | 22 | 55 | 13% |
Gender differences in pharmacokinetics and pharmacodynamics | 1999 | 118 | 107 | 12% |
Gender-related differences in pharmacokinetics and their clinical significance | 1999 | 132 | 75 | 11% |
The Menstrual Cycle and Drug Metabolism | 2009 | 4 | 92 | 32% |
Now important are gender differences in pharmacokinetics? | 2002 | 195 | 143 | 8% |
Sex Differences in Pharmacokinetics and Pharmacodynamics | 2009 | 57 | 90 | 10% |
GENDER EFFECTS IN PHARMACOKINETICS AND PHARMACODYNAMICS | 1995 | 318 | 138 | 13% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ENVIRONM INJURY EPIDEMIOL TOXICOL UNIT | 1 | 50% | 0.6% | 1 |
2 | ONCOL PHYSIOL | 1 | 50% | 0.6% | 1 |
3 | PHARM INFECT DIS | 1 | 50% | 0.6% | 1 |
4 | SUBDIRECC GEN MED USO HUMANO | 1 | 50% | 0.6% | 1 |
5 | UNIDAD FARMACOL CLIN EXPT | 1 | 50% | 0.6% | 1 |
6 | CIENCIAS SOCIAIS COMPORTAMENTO | 0 | 33% | 0.6% | 1 |
7 | SERV MED AQUITAINE | 0 | 33% | 0.6% | 1 |
8 | DRUG INFORMAT LEARNING OURCE | 0 | 25% | 0.6% | 1 |
9 | LL | 0 | 25% | 0.6% | 1 |
10 | OFF ENVIRONM HLTH SAFETY TOXICOL | 0 | 25% | 0.6% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000212401 | CLIN SUBDIRECT//ETHN//EXPLICIT IMPLICIT MEMORY |
2 | 0.0000201745 | ETHINYLESTRADIOL//GESTODENE//CAS 57 63 6 |
3 | 0.0000139314 | NORVERAPAMIL//CLIN PHARMACOL GERIATR MED//S VERAPAMIL |
4 | 0.0000135410 | WOMENS STUDIES MED//EVANS MEDWOMENS HLTH UNIT//GENDER SOCIAL DEV STUDIES |
5 | 0.0000128313 | TRIMETHADIONE//ZAKLAD CHEM FIZJOL//ZAKLAD CHEM FIZJOLOGICZNEJ |
6 | 0.0000117014 | MED HOSP PHARM YAHATANISHI KU//4 HYDROXYPROPRANOLOL//PROPRANOLOL METABOLISM |
7 | 0.0000114846 | CYP1A2//CAFFEINE METABOLISM//CYP1A2 ACTIVITY |
8 | 0.0000094593 | OVARIAN SEX HORMONES//PARTNERSHIP WOMENS HLTH//NOLL 106 |
9 | 0.0000079755 | CYP3A//COCKTAIL//MECHANISM BASED INHIBITION |
10 | 0.0000079654 | I 125 IOMAZENIL//ACQUISITION OF OPERANT BEHAVIOR//ACTIVE SHUTTLEBOX AVOIDANCE |